The treated patient achieved an overall partial response of 72% in tumor regression.
Noah Stansfield
Advertisement
Articles by Noah Stansfield
A multisite phase 1 clinical trial for NT-I7 is underway in patients with relapsed/refractory large B-cell lymphoma.
CTX130 is also being investigated for the treatment of r/r renal cell carcinoma in a phase 1 clinical trial called COBALT-RCC (NCT04438083).
Among treated patients, 42% achieved 5-year event free survival.
Advertisement
Advertisement
Advertisement
Trending on CGTlive®
1
Ultragenyx's Glycogen Storage Disease Gene Therapy DTX401 Continues to Enable Decreases in Reductions in Daily Cornstarch Intake at 96 Weeks
2
Sanofi’s Neovascular Age-Related Macular Degeneration Gene Therapy SAR402663 Garners FDA Fast Track Designation
3
